Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 15/20 | 0.37 |
| ▸ | TSPO | P30536 | 3/20 | 0.37 |
| ▸ | OXTR | P30559 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21379004 | 0.84 | TSPO (0.35) | AVPR1ATSPOOXTRDRD2DRD4 | |
| SCHEMBL29990044 | 0.83 | CHRM1 (0.34) | AVPR1ATSPOOXTRCHRM1 | |
| SCHEMBL21379060 | 0.83 | CHRM1 (0.34) | AVPR1ATSPOOXTRCHRM1 | |
| SCHEMBL21379279 | 0.83 | TSPO (0.34) | AVPR1ATSPOOXTRDRD2DRD4 | |
| SCHEMBL29990699 | 0.83 | TSPO (0.34) | AVPR1ATSPOOXTRDRD2DRD4 | |
| SCHEMBL20267114 | 0.82 | PDE3B (0.46) | AVPR1AOXTRCHRM1 | |
| SCHEMBL29989621 | 0.82 | PDE3B (0.46) | AVPR1AOXTRCHRM1 | |
| SCHEMBL1496015 | 0.81 | TSPO (0.48) | AVPR1ATSPOOXTR | |
| Hydrochloric Acid SCHEMBL25255088 | 0.80 | TSPO (0.47) | AVPR1ATSPOOXTR | |
| SCHEMBL1495917 | 0.79 | TSPO (0.37) | AVPR1ATSPOOXTRDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11033555-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | Kinoxis Therapeutics Pty Ltd (AU) | 2021-06-15 | — | — | US | disclosed |
| US-20190290658-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | Kinoxis Therapeutics Pty Ltd (AU) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290658-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | SLC18A2, SLC6A3, CES2 | AVPR1A 550/4885TSPO 1520/4885OXTR 149/4885 |
| US-11033555-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | SLC18A2, SLC6A3, CES2 | AVPR1A 550/4885TSPO 1520/4885OXTR 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.